Intranasal Foralumab Reduces Microglia in Alzheimer’s Patient
Tiziana Life SciencesLife Sciences announced positive results from a PET scan of an Alzheimer’s patient treated with their intranasal...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Innovation Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Tiziana Life SciencesLife Sciences announced positive results from a PET scan of an Alzheimer’s patient treated with their intranasal...
Akero Therapeutics announced new analyses from its 96-week Phase 2b HARMONY trial of efruxifermin (EFX) for pre-cirrhotic metabolic dysfunction-associated...
NurExone Biologic Inc. presented preclinical data at the ARVO annual meeting, demonstrating that its ExoPTEN therapy restored retinal activity...
Corvus Pharmaceuticals released interim Phase 1 data for soquelitinib, an oral ITK inhibitor, in patients with moderate to severe...
UTRx Inc. submitted an Investigational New Drug (IND) application to the FDA for UTRxM1-18, a novel therapeutic targeting c-MYC...
Kriya Therapeutics presented preclinical data at the ARVO Annual Meeting for KRIYA-825, a gene therapy candidate for Geographic Atrophy...
Spherix Global Insights’ analysis of over 2,300 patient charts reveals a global shift in IgA nephropathy (IgAN) treatment, driven...
Yamo Pharmaceuticals announced positive Phase 2 trial results for L1-79, a drug targeting core autism spectrum disorder (ASD) symptoms,...
PDS Biotechnology Corporation announced preclinical data on its investigational Infectimune®-based flu vaccine at the IMMUNOLOGY2025™ Annual Meeting. Studies conducted...
Cognition Therapeutics announced topline results from its Phase 2 MAGNIFY trial of zervimesine, an oral drug for geographic atrophy...